Clozapine is considered the drug of choice for treatment-resistant schizophrenia in guidelines globally, but it remains significantly underutilized. This is largely due to its range of side effects, ...
The risk for moderate neutropenia associated with clozapine therapy is low in patients with treatment-resistant schizophrenia, and the risk for severe neutropenia is minimal, new research showed. None ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results